Allergoid–mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring

Thumbnail Image
Download
downoload1-s2.0-S0091674921009684-main.pdf (3.71 MB)
Official URL
https://doi.org/10.1016/j.jaci.2021.06.012
Full text at PDC
Publication date

2022

Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Citations
Google Scholar
Exportar
DC QDC MarcXML RDF MODS METS ORE-ATOM
URI
https://hdl.handle.net/20.500.14352/71283
Citation
Abstract
Allergoid–mannan conjugates are novel vaccines for allergen-specific immunotherapy being currently assayed in phase 2 clinical trials. Allergoid–mannan conjugates target dendritic cells (DCs) and generate functional forkhead box P3 (FOXP3)-positive Treg cells, but their capacity to reprogram monocyte differentiation remains unknown.
Research Projects
Organizational Units
Journal Issue
Description
CRUE-CSIC (Acuerdos Transformativos 2021)
UCM subjects
Química , Biología molecular (Química) , Bioquímica (Química)
Unesco subjects
23 Química
Keywords
Collections
Artículos